JNJ:NYSEJohnson & Johnson Analysis

Johnson & Johnson is trading at $234.34, comfortably above its 20‑day (≈227) and 50‑day (≈233) moving averages and well above its 200‑day average (≈211), indicating a solid positioning within a neutral trend. The RSI of 58 suggests the stock is not yet overbought, while the MACD histogram is positive and the MACD signal is flagged as bullish, reinforced by an increasing volume trend. Fundamentally, the company delivered 10% revenue growth, maintains a 68% gross margin and a 27% operating margin, and generates a robust ROE of 26%. Cash flow remains strong with $22.1 bn cash on hand and free cash flow of $12.5 bn, supporting a dividend yield of 2.29% and a payout ratio of 60%, which is well within sustainable limits. Recent material news includes a positive clinical study for the OTTAVA robotic surgical system and an upgrade from Leerink Partners to Outperform, complemented by inclusion on Goldman Sachs’ Conviction List, all of which bolster investor confidence. Despite a modest upside of ~8% relative to the DCF‑derived fair value and a market‑wide “Extreme Greed” sentiment, the stock’s low beta (≈0.06) and defensive healthcare positioning mitigate broader market volatility.
Overall, the blend of solid earnings performance, dividend reliability, and favorable technical signals supports a cautiously optimistic stance, while the modest valuation premium over peers suggests the stock is fairly priced with limited upside potential in the near term.